XML 25 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements Of Operations And Comprehensive Loss (USD $)
In Thousands, except Share data, unless otherwise specified
 3 Months Ended 123 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Mar. 31, 2012
Costs and expenses:      
Research and development $ 422 $ 690 $ 42,007
Selling, general and administrative 984 1,512 40,340
Merger transaction costs     5,470
Restructuring expense, net     2,413
Loss on impairment of in-process research and development     6,000
Total costs and expenses 1,406 2,202 96,230
Loss from operations (1,406) (2,202) (96,230)
Gain on assignment of patent rights     2,000
Gain on bargain purchase     25,282
Interest and other income   1 2,026
Interest and other expense (1) (5) (440)
Loss before income taxes (1,407) (2,206) (67,362)
Benefit from income taxes     2,281
Net loss (1,407) (2,206) (65,081)
Less: Accretion of redeemable convertible preferred stock     (245)
Less: Deemed preferred stock dividend for additional common shares issuable under anti-dilution provisions     (781)
Net loss attributable to common stockholders (1,407) (2,206) (66,107)
Changes in other comprehensive income (loss)         
Comprehensive loss attributable to common stockholders $ (1,407) $ (2,206) $ (66,107)
Net loss attributable to common stockholders      
Basic and diluted $ (0.12) $ (0.25)  
Weighted average shares outstanding:      
Basic and diluted 12,166,301 8,817,837